AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2021
Oct 4, 2021
31523_dirs_2021-10-04_9f46e180-1c1e-4d9f-9e44-c7a8e0015d30.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2021-10-01
Reporting Person: WHITMAN BURKE W (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-10-01 | Common Stock | P | 1500 | $9.564 | Acquired | 63582 | Direct |
Footnotes
F1: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.45 to $9.58. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.